LSALT Peptide for Acute Kidney Injury During Cardiac Surgery
Trial Summary
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the drug LSALT Peptide for treating acute kidney injury during cardiac surgery?
What makes LSALT Peptide unique for treating acute kidney injury during cardiac surgery?
LSALT Peptide is unique because it targets inflammation and tissue damage specifically during cardiac surgery, which is a common cause of acute kidney injury (AKI). Unlike other treatments, it may offer a novel approach by focusing on reducing inflammation and protecting kidney tissues during the surgical process.12567
What is the purpose of this trial?
To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria:1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR3. Urine output \< 0.5 mL/kg/h for \>6 hours.
Eligibility Criteria
This trial is for adults over 18 who are undergoing on-pump cardiac surgery, such as bypass grafts or valve replacements. It's specifically for those with moderate chronic kidney disease (CKD Stage 3) and additional risk factors like diabetes or reduced heart function, or simply being aged 75 years or older.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive LSALT peptide or placebo intravenously twice daily for 5 days
Follow-up
Participants are monitored for safety and effectiveness after treatment, including kidney function assessments
Treatment Details
Interventions
- LSALT Peptide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arch Biopartners Inc.
Lead Sponsor